These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38783176)

  • 1. Effect of degalactosylated bovine glycoprotein formulations MAF and M сapsules on lymphopenia and clinical outcomes in hospitalized COVID-19 patients: a randomized clinical trial.
    Inui T; Kruglova O; Martynenko O; Martynenko K; Tieroshyn V; Gavrylov A; Kubo K; Yamakage H; Kutsyn B; Kubashko A; Veklych Z; Terashima Y; Mette M; Kutsyna G
    BMC Infect Dis; 2024 May; 24(1):519. PubMed ID: 38783176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.
    Zhang J; Xu D; Xie B; Zhang Y; Huang H; Liu H; Chen H; Sun Y; Shang Y; Hashimoto K; Yuan S
    Brain Behav Immun; 2020 Aug; 88():50-58. PubMed ID: 32512133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.
    Cheng LL; Guan WJ; Duan CY; Zhang NF; Lei CL; Hu Y; Chen AL; Li SY; Zhuo C; Deng XL; Cheng FJ; Gao Y; Zhang JH; Xie JX; Peng H; Li YX; Wu XX; Liu W; Peng H; Wang J; Xiao GM; Chen PY; Wang CY; Yang ZF; Zhao JC; Zhong NS
    JAMA Intern Med; 2021 Jan; 181(1):71-78. PubMed ID: 32910179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-dose
    Aghasadeghi MR; Zaheri Birgani MA; Jamalimoghadamsiyahkali S; Hosamirudsari H; Moradi A; Jafari-Sabet M; Sadigh N; Rahimi P; Tavakoli R; Hamidi-Fard M; Bahramali G; Parmoon Z; Arjmand Hashjin S; Mirzajani G; Kouhkheil R; Roshangaran S; Khalaf S; Khademi Nadoushan M; Gholamiyan Yousef Abad G; Shahryarpour N; Izadi M; Zendedel A; Jahanfar S; Dadras O; SeyedAlinaghi S; Hackett D
    Front Immunol; 2024; 15():1332425. PubMed ID: 38655258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial.
    Spadera L; Lugarà M; Spadera M; Conticelli M; Oliva G; Bassi V; Apuzzi V; Calderaro F; Fattoruso O; Guzzi P; D'Amora M; Catapano O; Marra R; Galdo M; Zappalà M; Inui T; Mette M; Vitiello G; Corvino M; Tortoriello G
    Biomed Pharmacother; 2023 Dec; 169():115894. PubMed ID: 37988850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
    Balevic SJ; Benjamin DK; Powderly WG; Smith PB; Gonzalez D; McCarthy MW; Shaw LK; Lindsell CJ; Bozzette S; Williams D; Linas BP; Blamoun J; Javeri H; Hornik CP;
    JAMA Netw Open; 2024 Apr; 7(4):e247615. PubMed ID: 38662372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
    Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
    JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.
    Poulakou G; Royer PJ; Evgeniev N; Evanno G; Shneiker F; Marcelin AG; Vanhove B; Duvaux O; Marot S; Calvez V
    Front Immunol; 2024; 15():1330178. PubMed ID: 38694503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
    Diaz R; Orlandini A; Castellana N; Caccavo A; Corral P; Corral G; Chacón C; Lamelas P; Botto F; Díaz ML; Domínguez JM; Pascual A; Rovito C; Galatte A; Scarafia F; Sued O; Gutierrez O; Jolly SS; Miró JM; Eikelboom J; Loeb M; Maggioni AP; Bhatt DL; Yusuf S;
    JAMA Netw Open; 2021 Dec; 4(12):e2141328. PubMed ID: 34964849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.